Header Logo

Connection

Johnny Mahlangu to Adult

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Adult.
Johnny Mahlangu
Connection Strength
2,302
Adult
  1. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
    View in: PubMed
    Score: 0,108
  2. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248.
    View in: PubMed
    Score: 0,097
  3. Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis. J Clin Pathol. 2023 Aug; 76(8):555-560.
    View in: PubMed
    Score: 0,097
  4. Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
    View in: PubMed
    Score: 0,094
  5. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580.
    View in: PubMed
    Score: 0,088
  6. Immunoglobulin subtyping and quantification in direct antiglobulin test: positive haemolysis in an HIV-prevalent setting. J Clin Pathol. 2022 Feb; 75(2):117-120.
    View in: PubMed
    Score: 0,086
  7. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
    View in: PubMed
    Score: 0,082
  8. Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. S Afr Med J. 2019 Aug 28; 109(9):639-644.
    View in: PubMed
    Score: 0,078
  9. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
    View in: PubMed
    Score: 0,077
  10. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
    View in: PubMed
    Score: 0,076
  11. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb; 34(1):44-50.
    View in: PubMed
    Score: 0,075
  12. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,074
  13. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,073
  14. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
    View in: PubMed
    Score: 0,064
  15. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879.
    View in: PubMed
    Score: 0,064
  16. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
    View in: PubMed
    Score: 0,063
  17. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
    View in: PubMed
    Score: 0,063
  18. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7.
    View in: PubMed
    Score: 0,063
  19. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
    View in: PubMed
    Score: 0,062
  20. Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86.
    View in: PubMed
    Score: 0,058
  21. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
    View in: PubMed
    Score: 0,053
  22. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
    View in: PubMed
    Score: 0,047
  23. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia. 2009 Jan; 15(1):135-41.
    View in: PubMed
    Score: 0,037
  24. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
    View in: PubMed
    Score: 0,027
  25. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
    View in: PubMed
    Score: 0,026
  26. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
    View in: PubMed
    Score: 0,025
  27. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
    View in: PubMed
    Score: 0,023
  28. A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa. Afr Health Sci. 2021 Dec; 21(4):1764-1775.
    View in: PubMed
    Score: 0,023
  29. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
    View in: PubMed
    Score: 0,023
  30. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
    View in: PubMed
    Score: 0,022
  31. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,022
  32. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
    View in: PubMed
    Score: 0,022
  33. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020 09 29; 21(1):415.
    View in: PubMed
    Score: 0,021
  34. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271.
    View in: PubMed
    Score: 0,021
  35. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,020
  36. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,019
  37. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One. 2018; 13(10):e0204899.
    View in: PubMed
    Score: 0,018
  38. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920.
    View in: PubMed
    Score: 0,018
  39. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
    View in: PubMed
    Score: 0,017
  40. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
    View in: PubMed
    Score: 0,017
  41. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,017
  42. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.
    View in: PubMed
    Score: 0,016
  43. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
    View in: PubMed
    Score: 0,016
  44. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
    View in: PubMed
    Score: 0,016
  45. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
    View in: PubMed
    Score: 0,016
  46. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,016
  47. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76.
    View in: PubMed
    Score: 0,015
  48. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
    View in: PubMed
    Score: 0,014
  49. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97.
    View in: PubMed
    Score: 0,014
  50. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
    View in: PubMed
    Score: 0,014
  51. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
    View in: PubMed
    Score: 0,014
  52. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015 Jan; 168(1):124-34.
    View in: PubMed
    Score: 0,014
  53. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53.
    View in: PubMed
    Score: 0,014
  54. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
    View in: PubMed
    Score: 0,014
  55. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
    View in: PubMed
    Score: 0,013
  56. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9.
    View in: PubMed
    Score: 0,012
  57. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009 Apr; 99(4):243-8.
    View in: PubMed
    Score: 0,010
  58. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
    View in: PubMed
    Score: 0,009
  59. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001 Jun; 10(2):95-9.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.